IP Library Granted Patent US 8,206,757
Granted Patent B2
US 8,206,757 · App. 12/604,092 · Granted Jun 26, 2012

Composition of ashwagandha and indian gooseberry

Assignees: Nutragenesis, LLC; Natreon, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,206,757
App. No.
12/604,092
Granted
Jun 26, 2012
Kind
B2
Abstract

A therapeutic composition comprising extracts of the plant species ashwagandha ( Withania somnifera ) and Indian gooseberry ( Phyllanthus emblica ). A composition of ashwagandha and Indian gooseberry may: (1) lower cortisol and increase DHEA, (2) prevents free radical-induced photoaging, (3) inhibit collagenase activity in vitro, (4) inhibit hyaluronidase activity in vitro, (5) display superior cascading antioxidant activity, (6) reduce C-reactive protein, (7) enhance mood.

Claims (12)

1. A therapeutic composition for internal use by a human subject in the reduction of premature skin aging consisting essentially of a skin age reducing synergistically effective combination of an extract of Phyllanthus emblica and an extract of Withania somnifera wherein said Phyllanthus emblica and said Withania somnifera are present in the composition in a weight ratio of about 1:7 Phyllanthus emblica to Withania somnifera to a weight ratio of about 7:1 Phyllanthus emblica to Withania somnifera.

2. The therapeutic composition according to claim 1 , wherein said Phyllanthus emblica and said Withania somnifera are present in the composition in a weight ratio of about 6:2 Phyllanthus emblica to Withania somnifera to a weight ratio of about 2:6 Phyllanthus emblica to Withania somnifera.

3. The therapeutic composition according to claim 1 , wherein the Phyllanthus emblica and Withania somnifera are present in the composition in a weight ratio of about 6:2 Phyllanthus emblica to Withania somnifera to a weight ratio of about 3:5 Phyllanthus emblica to Withania somnifera.

4. The therapeutic composition according to claim 1 , wherein the Phyllanthus emblica and Withania somnifera are present in the composition in a weight ratio of about 6:2 Phyllanthus emblica to Withania somnifera to a weight ratio of about 2:2 Phyllanthus emblica to Withania somnifera.

5. The therapeutic composition according to claim 1 , wherein the Phyllanthus emblica and Withania somnifera are present in the composition in a weight ratio of about 5:3.

6. The therapeutic composition according to claim 1 , comprising about 60 wt. % Withania somnifera to about 65 wt. % Withania somnifera and about 35 wt. % Phyllanthus emblica to about 40 wt. % Phyllanthus emblica.

7. The therapeutic composition according to claim 1 , wherein said synergistically effective combination includes Phyllanthus emblica to Withania somnifera in a weight to weight ratio that is effective to synergistically inhibit collagenase.

8. The therapeutic composition according to claim 7 , wherein said synergistically effective combination includes Phyllanthus emblica to Withania somnifera in a weight to weight ratio that is effective to provide at least a 50% activity inhibition of collagenases Type I and Type IV.

9. The therapeutic composition according to claim 1 , wherein said synergistically effective combination includes Phyllanthus emblica to Withania somnifera in a weight to weight ratio that is effective to synergistically inhibit hyaluronidase.

10. The therapeutic composition according to claim 9 , wherein said synergistically effective combination includes Phyllanthus emblica to Withania somnifera in a weight to weight ratio that is effective to provide at least 86% inhibition of hyaluronidase activity at 1:1000.

11. The therapeutic composition according to claim 1 , wherein said synergistically effective combination includes Phyllanthus emblica to Withania somnifera in a weight to weight ratio that is effective to provide an ORAC (Oxygen Radical Absorbance Capacity) value of at least 967 μmole Trolox equivalents/g.

12. The therapeutic composition according to claim 1 , wherein said synergistically effective combination includes Phyllanthus emblica to Withania somnifera in a weight to weight ratio that is effective to provide an HORAC (Hydroxyl Radical Antioxidant Capacity) value of 154 μmole caffeic acid equivalents/g.

Assignments (8)
SECURITY INTEREST Recorded Jan 6, 2025
From: INNOPHOS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT
Reel/Frame 069749/0211 →
CHANGE OF NAME Recorded Mar 13, 2020
From: NOVEL INGREDIENT SERVICES, LLC
To: INNOPHOS, LLC
Reel/Frame 052164/0808 →
MERGER Recorded Feb 20, 2020
From: NUTRAGENESIS, LLC
To: NOVEL INGREDIENT SERVICES, LLC
Reel/Frame 051876/0164 →
PATENT SECURITY AGREEMENT (TL) Recorded Feb 10, 2020
From: INNOPHOS, INC.; INNOPHOS, LLC
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 051858/0161 →
PATENT SECURITY AGREEMENT (ABL) Recorded Feb 10, 2020
From: INNOPHOS, INC.; INNOPHOS, LLC
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 051858/0131 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2020
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: NUTRAGENESIS, LLC
Reel/Frame 051749/0764 →
SECURITY INTEREST Recorded Jan 17, 2018
From: NUTRAGENESIS, LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 044645/0115 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2009
From: MCNEARY, PETER
To: NUTRAGENESIS, LLC
Reel/Frame 023411/0441 →
Continuity (2)
Provisional Application 61107573 · Oct 22, 2008
Related Publication 20100098785A1 · Apr 22, 2010